dystrophin production

Weekly treatment with eteplirsen resulted in a 69.4-meter benefit on the 6-minute walk compared to placebo/delayed treatment; study extends earlier results showing eteplirsen caused dystrophin production

posted on July 24, 2012 - 10:55am
Editor's note (July 24, 2012): For a more in-depth discussion of the exon-skipping trial results, see A Closer Look: Extended Eteplirsen Treatment Benefits Walking in DMD.

AVI BioPharma has begun phase 2 testing of its experimental exon-skipping drug eteplirsen (AVI-4658) in boys with Duchenne MD

posted on August 15, 2011 - 11:37am
Updated: View MDA's video about the launch of the eteplirsen trial on YouTube.

Complete results of a U.K. trial of an exon-skipping drug in boys with DMD show drug is safe, increases dystrophin production

posted on July 26, 2011 - 11:24am
Complete and extremely encouraging findings from a phase 1b-2 trial of eteplirsen (AVI-4658), an exon skipping drug in development to treat a portion of the Duchenne muscular dystrophy (DMD) population, show the compound is safe and well-tolerated, and that it can significantly increase production of the needed dystrophin protein in recipients without eliciting an unwanted immune response.

Further analysis of data from a trial of the exon-skipping drug AVI4658 showed some participants had greatly increased dystrophin production

posted on June 2, 2010 - 10:15am
The biopharmaceutical company AVI BioPharma has announced additional encouraging results from its clinical trial of AVI4658, an experimental treatment for Duchenne muscular dystrophy (DMD). The new results show that, at higher doses, AVI4658 can result in substantial production of the needed dystrophin protein in muscle fibers. The company has not yet released results of any tests of muscle...